Good morning,Today the Wall Street Journal reported, in its online edition, Boston Scientificis is moving closer to striking a deal to buy the 80 percent it doesn't already own of Isreali medical device concern Medinol.Boston Scientific currently holds 22 pct of Medinol while the Israeli company's founders -- Kobi and Judith Richter -- own 64 percent and another founder holds the rest. Medinol employs 150 people in Israel. Medinol has developed a range of new stents under the NIR trade name, including the NIRFLEX, with improved rigidity and flexibility. According to the source, the problem has been delays in the development of delivery systems for the new stents. While Medinol develops the stents, Boston Scientific makes the delivery devices, called balloons. According to the source Medinol's value lies not only in its stents but also in its efficient manufacturing process, resulting in low production costs and profit margins of up to 90 percent. To see the entire story click on the news link @ the top of this page.Best wishes,Spirit
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra